Switching Fractioned R-CHOP Cycles to Standard R-CHOP Cycles Guided by Endoscopic Ultrasonography in Treating Patients with Primary Gastric Diffuse Large B-Cell Lymphoma

Authors

Yizhen Liu
Yumei Liu
Ping Zhao
Qunling Zhang
Xiaojian Liu
Junning Cao
Kai Xue

Document Type

Article

Publication Title

Cancer Management and Research

Abstract

Primary gastric diffuse large B-cell lymphoma (PG-DLBCL) is a common subtype of extranodal non-Hodgkin lymphoma (NHL), with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) as the commonly used treatment regimen. However, full cycles of standard R-CHOP present the risk of severe bleeding or perforation, even leading to emergency surgery, especially for those with deep lesions in their first 1–2 cycles of treatment. This study aims to explore the safety and efficacy of fractioned R-CHOP (rituximab d0, 50%dose of CHOP d1 and d5) followed by standard R-CHOP cycles in PG-DLBCL patients guided by endoscopic ultrasonography (EUS).

First Page

5041

Last Page

5048

Publication Date

2020

Recommended Citation

Liu, Yizhen; Liu, Yumei; Zhao, Ping; Zhang, Qunling; Liu, Xiaojian; Cao, Junning; and Xue, Kai, "Switching Fractioned R-CHOP Cycles to Standard R-CHOP Cycles Guided by Endoscopic Ultrasonography in Treating Patients with Primary Gastric Diffuse Large B-Cell Lymphoma" (2020). Biology. 3.
https://roar.una.edu/biology/3